In short
Clinical trials are underway to assess the safety, tolerability, and immunogenicity of V116, a new 21-valent pneumococcal conjugate vaccine. These studies aim to evaluate V116 in various populations at increased risk for pneumococcal disease, including adults, children, and adolescents. The trials compare V116 to existing pneumococcal vaccines and measure immune responses and adverse events following vaccination.
At a glance
- Vaccine
- V116 (21-valent pneumococcal conjugate vaccine)
- Study Populations
- Adults 18-64 with risk factors, adults 50+, children/adolescents at risk
- Primary Objectives
- Evaluate safety, tolerability, and immunogenicity
- Comparator Vaccines
- PPSV23, PCV15
- Key Measurements
- OPA antibody levels, IgG concentrations, adverse events
- Administration
- 0.5 mL intramuscular injection
- Follow-up Period
- 30 days post-vaccination for primary endpoints
What is ABC-23A-116?
ABC-23A-116 is a new vaccine being developed to protect against pneumococcal disease. It is part of a larger vaccine called V116, which is a 21-valent pneumococcal conjugate vaccine. This means it targets 21 different types (serotypes) of pneumococcal bacteria. ABC-23A-116 specifically refers to one of the components in this vaccine that targets the 23A serotype of pneumococcus.
Purpose of ABC-23A-116
The main purpose of ABC-23A-116, as part of the V116 vaccine, is to prevent pneumococcal infections. These infections can cause serious diseases like pneumonia, meningitis, and bloodstream infections. The vaccine is being developed to protect people who are at increased risk of pneumococcal disease, including adults, children, and adolescents with certain medical conditions.
How ABC-23A-116 Works
ABC-23A-116 works by stimulating the body's immune system to produce antibodies against the 23A serotype of pneumococcal bacteria. It is a conjugate vaccine, which means the bacterial sugar (polysaccharide) is attached to a carrier protein called CRM197. This combination helps to create a stronger and longer-lasting immune response, especially in young children.
Ongoing Clinical Trials
Several clinical trials are currently being conducted to evaluate the safety and effectiveness of the V116 vaccine, which includes ABC-23A-116. These trials are focusing on different groups of people:
- Adults aged 18 to 64 years who are at increased risk of pneumococcal disease
- Adults aged 50 years and older
- Children and adolescents with increased risk of pneumococcal disease
These trials are measuring how well the vaccine stimulates the immune system and monitoring for any side effects. They are comparing V116 to existing pneumococcal vaccines to see if it provides better protection.
Who Can Receive ABC-23A-116?
The V116 vaccine, which includes ABC-23A-116, is being studied in people who are at higher risk for pneumococcal disease. This includes:
- Adults with certain medical conditions such as diabetes, chronic liver disease, chronic lung disease, chronic heart disease, or chronic kidney disease
- Adults aged 50 years and older
- Children and adolescents with increased risk of pneumococcal disease due to medical conditions like diabetes, chronic liver disease, chronic lung disease, chronic heart disease, or chronic kidney disease
It's important to note that the vaccine is still in clinical trials and is not yet available for general use.
Potential Benefits and Risks
The potential benefits of ABC-23A-116, as part of the V116 vaccine, include protection against pneumococcal infections caused by the 23A serotype. This could help prevent serious illnesses like pneumonia, meningitis, and bloodstream infections in people at high risk.
As with any vaccine, there may be some risks or side effects. The clinical trials are carefully monitoring for any adverse events. Common side effects of vaccines can include pain at the injection site, fatigue, headache, and muscle pain. More serious side effects are rare but are being closely watched for in the trials.
Conclusion
ABC-23A-116 is a promising component of the new V116 pneumococcal vaccine. While it's still in the testing phase, it has the potential to provide improved protection against pneumococcal disease for people at high risk. As research continues, we'll learn more about its effectiveness and safety profile. If you're interested in learning more about this vaccine or think you might be eligible for a clinical trial, it's best to speak with your healthcare provider.